Showing 2081-2090 of 4063 results for "".
- Iantrek Hits 2,000 Procedures for New Bio-Interventional Technology - AlloFlo Uveohttps://modernod.com/news/iantrek-hits-2000-procedures-for-new-bio-interventional-technology-alloflo-uveo/2482785/Iantrek announced it has surpassed 2,000 AlloFlo Uveo procedures in the US. The key milestone comes ahead of its full commercial launch planned for this fall during the American Academy of Ophthalmology 2025 meeting. Recent momentum has been fueled by the publication of 2-year
- Nanoscope Announces Topline Results from Phase 2b Trial of MCO-010 for Retinitis Pigmentosahttps://modernod.com/news/nanoscope-announces-topline-results-from-randomized-phase-2b-trial-of-mco-010-for-retinitis-pigmentosa/2482183/Nanoscope Therapeutics announced positive topline results after the completion of the 2-year phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010, a mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced retini
- Nanoscope Therapeutics Wins 'Best of Show' Award at AAO Eyecelerator 2023https://modernod.com/news/nanoscope-therapeutics-wins-best-of-show-award-at-aao-eyecelerator-2023/2481955/Nanoscope Therapeutics was awarded the 'Best of Show in Retina' award at this year's American Academy of Ophthalmology (AAO) Eyecelerator conference held in San Francisco on Thursday, November 2, 2023. During the conference, Samuel Barone, MD, Nanoscope's chief
- Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-receives-fda-clearance-of-ind-application-for-atsn-201-an-investigational-gene-therapy-for-the-treatment-of-x-linked-retinoschisis/2481580/Atsena Therapeutics, a clinical-stage gene therapy company, announced the FDA has cleared the company’s investigational new drug (IND) application for a phase 1/2 clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS). ATSN-201 leverages one of the company&rsquo
- MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the ARVO 2022 Annual Meetinghttps://modernod.com/news/meiragtx-presents-clinical-data-on-botaretigene-sparoparvovec-for-the-treatment-of-x-linked-retinitis-pigmentosa-at-the-arvo-2022-annual-meeting/2480844/MeiraGTx Holdings plc announced that additional clinical data from the phase 1/2 trial of botaretigene sparoparvovec for the treatment of x-linked retinitis pigmentosa (XLRP) were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting in Denver, Colo
- Global Data: Primary Open Angle Glaucoma Total Prevalent Cases to Reach 8.84 Million by 2030https://modernod.com/news/global-data-primary-open-angle-glaucoma-total-prevalent-cases-to-reach-884-million-by-2030/2480534/The burden of total prevalent cases (diagnosed and undiagnosed) of primary open angle glaucoma (POAG) is expected to increase at an annual growth rate (AGR) of 2% from around 7.3 million cases in 2020 to 8.84 million in 2030 in the seven major markets, according to GlobalData. The increase is par
- MeiraGTx Announces Data at EURETINA 2021 Demonstrating Reversal of Disease Progression Following Treatment With AAV5-RPGR in XLRPhttps://modernod.com/news/meiragtx-announces-data-at-euretina-2021-demonstrating-reversal-of-disease-progression-following-treatment-with-aav5-rpgr-in-xlrp/2479499/MeiraGTx Holdings announced new data from subjects treated in the phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP), reverses course of disease progression when retinal fun
- Envision Sets Agenda for 2021 Virtual Conference Easthttps://modernod.com/news/envision-sets-agenda-for-2021-virtual-conference-east/2479371/Envision announced that it has finalized the agenda for its August 2021 Conference, a 2-day event to be livestreamed on August 20-21. Envision Virtual Conference East 2021 is a multidisciplinary event focused on disseminating the latest advancements in rehabilitation techniques and research and t
- Ocuphire’s APX3330 for Retinal Diseases to be Presented at ARVO 2021https://modernod.com/news/ocuphires-apx3330-for-retinal-diseases-to-be-presented-at-arvo-2021/2479102/Ocuphire Pharma announced that data from preclinical studies and pharmacokinetic modeling of the company’s proprietary APX3330 drug candidate will be presented on Sunday, May 2, 2021 during the Association for Research in Vision and Ophthalmology (ARVO) virtual Annual Meeting, May 1-7, 2021.
- Topcon Announces eyeRISE 2021 Virtual Symposia & Expohttps://modernod.com/news/topcon-announces-eyerise-2021-virtual-symposia-expo/2478765/Topcon Healthcare announced it will host a 2-day virtual symposia and expo called eyeRISE, on February 9-10, 2021. eyeRISE, or Eye Research Innovation Symposia & Expo, is a new, multi-disciplinary virtual congress showcasing the latest innovations in eye care. It will feature three sol